Table 2.
Comparison of HPV16/18-Specific Cytokine Responses in the 0-, 1-, or 2-Dose Group with the 3-Dose Group 6 Years After 4vHPV and 1 Month After a Booster Dose of 2vHPV
| Dosage Groups/ Cytokines |
Pre-2vHPV | Post-2vHPV | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| a3 Dose (n = 15) | 2 Dose (n = 14) | 1 Dose (n = 15) | 0 Dose (n = 15) | a3 Dose (n = 15) | 2 Dose (n = 14) | 1 Dose (n = 15) | 0 Dose (n = 15) | |||||||
| Mean (95% CI), pg/mL |
Mean (95% CI), pg/mL |
P Value | Mean (95% CI), pg/mL |
P Value | Mean (95% CI), pg/mL |
P Value | Mean (95% CI), pg/mL |
Mean (95% CI), pg/mL |
P Value | Mean (95% CI), pg/mL |
P Value | Mean (95% CI), pg/mL |
P Value | |
| HPV16 | ||||||||||||||
| IFNγ | 69.9 (20.9 to 119.0) |
31.9 (5.7 to 58.2) |
.093 | 65.8 (10.2 to 121.5) |
0.430 | 18.3 (–5.5 to 42.1) |
.001 | 193.2 (92.1 to 294.2) |
123.8 (34.9 to 212.8) |
.146 | 91.1 (24.2 to 157.9) |
.029 | 44.6 (–4.4 to 93.5) |
<.001 |
| IL-2 | 30.1 (16.4 to 43.8) |
19.4 (3.0 to 35.8) |
.022 | 14.8 (5.1 to 24.5) |
0.040 | 6.0 (2.6 to 9.3) |
<.001 | 54.8 (35.4 to 74.3) |
61.6 (38.8 to 84.4) |
.591 | 41.9 (6.0 to 77.7) |
.057 | 16.0 (6.4 to 25.6) |
<.001 |
| TNFα | 93.5 (60.0 to 127.1) |
81.4 (24.7 to 138.1) |
.217 | 102.4 (34.8 to 170.1) |
0.595 | 43.7 (16.9 to 70.5) |
.003 | 176.7 (93.6 to 259.8) |
137.7 (81.5 to 193.9) |
.354 | 140.8 (41.3 to 240.4) |
.098 | 70.9 (34.3 to 107.5) |
.004 |
| IL-10 | 11.6 (7.9 to 15.2) |
15.1 (–2.1 to 32.3) |
.120 | 17.8 (5.0 to 30.7) |
0.751 | 8.7 (2.3 to 15.1) |
.046 | 44.5 (28.9 to 60.2) |
43.8 (20.9 to 66.6) |
.591 | 45.1 (3.8 to 86.4) |
.032 | 15.2 (7.7 to 22.7) |
<.001 |
| IL-5 | 4.2 (1.4 to 7.0) |
4.6 (0.5 to 8.7) |
.659 | 3.4 (0.9 to 5.9) |
0.298 | 3.4 (2.4 to 4.4) |
.736 | 13.2 (1.6 to 24.7) |
12.9 (7.0 to 18.8) |
.41 | 14.8 (–3.5 to 33.1) |
.055 | 5.9 (2.7 to 9.1) |
.164 |
| HPV18 | ||||||||||||||
| IFNγ | 17.3 (8.6 to 26.1) |
3.6 (1.7 to 5.6) |
.002 | 14.8 (2.3 to 27.2) |
0.132 | 2.8 (0.7 to 4.9) |
<.001 | 25.3 (5.8 to 44.9) |
18.1 (3.1 to 33.1) |
.331 | 24.4 (–1.8 to 50.7) |
.043 | 6.0 (0.0 to 11.9) |
<.001 |
| IL-2 | 15.1 (7.3 to 22.9) |
4.4 (1.2 to 7.6) |
.013 | 8.3 (1.3 to 15.2) |
0.031 | 3.8 (1.5 to 6.0) |
.026 | 22.4 (10.5 to 34.3) |
21.5 (12.2 to 30.7) |
.949 | 21.0 (0.9 to 41.0) |
.068 | 8.2 (3.3 to 13.2) |
.015 |
| TNFα | 57.9 (42.9 to 72.9) |
50.3 (5.5 to 95.04) |
.016 | 52.1 (27.8 to 76.3) |
0.461 | 31.2 (21.1 to 41.4) |
.005 | 103.9 (28.1 to 179.8) |
53.6 (39.3 to 67.9) |
.377 | 132.8 (–21.7 to 287.3) |
.098 | 102.5 (–16.4 to 221.4) |
.267 |
| IL-10 | 8.6 (5.6 to 11.7) |
7.3 (–1.0 to 15.7) |
.018 | 4.2 (2.3 to 6.1) |
0.014 | 5.6 (3.3 to 8.0) |
.099 | 15.3 (9.2 to 21.3) |
9.7 (6.9 to 12.6) |
.158 | 33.0 (–12.6 to 78.5) |
.060 | 13.4 (–0.5 to 27.2) |
.044 |
| IL-5 | 4.4 (0.8 to 8.1) |
2.1 (1.0 to 3.3) |
.470 | 2.5 (0.7 to 4.2) |
0.530 | 3.6 (2.5 to 4.6) |
.243 | 6.5 (0.6 to 12.3) |
5.1 (2.7 to 7.5) |
.723 | 7.6 (–1.1 to 16.2) |
.289 | 3.8 (2.6 to 4.9) |
.943 |
Abbreviations: 2vHPV, Cervarix, GSK; CI, confidence interval; pre-2vHPV, 6 years after 4vHPV; post-2vHPV, 1 month after a booster dose of 2vHPV.
aComparison group.